Pomerantz Law Firm Announces Class Action Lawsuit Against Erasca, Inc. Amid Allegations of Securities Fraud

Investor Alert: Class Action Lawsuit Against Erasca, Inc.

On July 9, 2026, the Pomerantz Law Firm publicly alerted investors of a legal matter involving Erasca, Inc. (NASDAQ: ERAS). A class action lawsuit has been initiated against the company, raising serious allegations related to securities fraud and other potential wrongdoing by its management.

Background of the Lawsuit

Erasca, known for its focus on transforming cancer treatment, is now under scrutiny following reports of a legal challenge from Revolution Medicines, Inc. (RevMed). The lawsuit claims that Erasca's ERAS-0015 product infringes upon RevMed's patent and involves the alleged misappropriation of trade secrets. RevMed's letter, received by Erasca on April 27, 2026, accuses the company of making misleading public comparisons between ERAS-0015 and RMC-6236—another cancer treatment product. Investors who have suffered losses as a result are encouraged to reach out to Pomerantz at their contact number or email for assistance.

Investor Implications and Deadlines

For investors affected during the class period, a critical deadline is approaching—August 10, 2026. By this date, they can request to be appointed as Lead Plaintiff for the class. This provides an opportunity for investors to seek recourse for their losses and hold Erasca accountable for its alleged actions. Investors interested in joining the class action are advised to obtain a copy of the complaint, which is available on Pomerantz's website.

Stock Response to Allegations

Following the allegations made by RevMed, Erasca experienced a significant drop in stock value. On April 27, 2026, the company's shares plummeted $2.34 (10.71%), closing at $19.50. The situation escalated further when preliminary Phase 1 clinical data concerning ERAS-0015 was disclosed. This included the unfortunate report of a patient's death linked to the treatment, which led to a drastic decline in share price to $9.90—down $9.25 (48.3%) on April 28, 2026.

About Pomerantz Law Firm

With over 85 years of experience, Pomerantz LLP is recognized as a leader in corporate and securities law, fighting for investors' rights. Founded by Abraham L. Pomerantz, the firm has a rich history in securities class actions and has secured substantial damages for class members in various cases. Their offices span across major cities including New York, Chicago, and London, showcasing their wide-reaching impact and commitment to serving investors.

For more information, affected individuals are encouraged to contact Danielle Peyton at Pomerantz Law Firm via phone or email. As the details of this lawsuit continue to unfold, it's essential for investors to stay informed and act promptly to protect their interests.

This ongoing legal case will serve as a crucial moment for both the company and its investors as the actions taken in the coming months could define the future of Erasca and the faith of its stakeholders. Timeliness is key—investors are urged to ensure they adhere to all relevant deadlines and keep abreast of further developments.